The company formed a partnership with Genzyme to collaborate on its vector technology and viral-based products.

In 1999 the company founded Galapagos Genomics as a joint venture together with Tibotec.

[citation needed] In 2006, Crucell and Swiss Berna Biotech; Swedish SBL Vaccines and US-based Berna Products joined forces to become the sixth largest vaccine company worldwide, with their own clinical programs.

[1] This followed Crucell's discovery of CR6261, a potent human antibody that neutralizes a broad range of influenza A viruses.

Initial production of the vaccine is happening at Janssen Biotech in Leiden, Netherlands.